Therapeutic or Preventive Procedure – Page 93

Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology

1 year ago talkbio0Tagged Acquisition (action), Biotechnology, Drug Development, Escient, expansion, G-Protein-Coupled Receptors, Immune system, Incyte, Neuroscience discipline, portfolio, targets

Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.

ImmunityBio’s Innovative IL-15 Superagonist Receives FDA Approval for Non-Muscle Invasive Bladder Cancer Treatment

1 year ago talkbio0Tagged Approved, Carcinoma of urinary bladder, invasive, ImmunityBio, Immunotherapy, Interleukin-15, Malignant Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Superagonist, United States Food and Drug Administration

ImmunityBio, FDA Approval, IL-15 Superagonist, Non-Muscle Invasive Bladder Cancer (NMIBC), Immunotherapy, Cancer Treatment

Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases

1 year ago1 year ago talkbio0Tagged boehringer ingelheim, Chronic liver disease, Collaboration, Drug Discovery, Fibrosis, Liver, Nonalcoholic Steatohepatitis, RNA

Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)

BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

1 year ago talkbio0Tagged Automation, Biotechnology, Burning Mouth Syndrome, Cancer Therapeutic Procedure, Capacity, CAR-T, Cell Therapy, Cellares, expansion, Investments, Manufacture, squibb

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.

Ipsen and Skyhawk Therapeutics Join Forces in a $1.8 Billion Deal to Advance RNA Modulator Research

1 year ago talkbio0Tagged Biological Factors, development aspects, Drug Discovery, Ipsen, Partnership, R&D, RNA modulators, Skyhawk

Ipsen, Skyhawk Therapeutics, RNA modulators, drug discovery, partnership, $1.8 billion, biopharmaceutical, R&D, therapeutic development

FDA Approves Takeda’s Subcutaneous Entyvio Injection for Maintenance Therapy in Moderate to Severe Crohn’s Disease

1 year ago talkbio0Tagged Crohn 's disease, Entyvio, Injection of therapeutic agent, Maintenance therapy, subcutaneous, Takeda, United States Food and Drug Administration

FDA, Takeda, Entyvio, Subcutaneous, Injection, Maintenance Therapy, Crohn’s Disease

Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce

1 year ago talkbio0Tagged Acorda, Biological Factors, Biopharma layoffs, Cara, Eiger, Fujifilm, Genomic Orientation, Invitae, Pfizer, sanofi, Vedanta

Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer